Physician profile
Mina Kim
NPI 1568704054
$696.49
in general payments reported to CMS, 2019-2025
11 companies · $267 in 2025
The $267 reported for 2025 was more than what 85% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.18 · 2020: $107 · 2021: $77.41 · 2022: $68.28 · 2023: $43.59 · 2024: $119 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $312.71 | 2019-2025 | |
| Abiomed | $120.93 | 2025 | |
| Baxter Healthcare | $55.23 | 2024 | Perclot |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.35 | 2020-2025 | Relistor |
| Ardelyx, INC. | $33.32 | 2025 | Ibsrela |
| Janssen Biotech, INC. | $33.12 | 2024-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $21.62 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $19.81 | 2025 | Entyvio |
| Braintree Laboratories, INC. | $19.75 | 2024 | Suflave |
| Celltrion USA INC. | $18.27 | 2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $14.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.